SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending as investor skepticism intensifies over the company's new $2,195 AR smart glasses, with many questioning the product's high price point and its viability in a crowded market. The community remains deeply divided, with some betting on the long-term potential of its AR ecosystem and large user base, while others advocate for a leadership change or a potential buyout, citing ongoing frustrations with management and stagnant stock performance.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is seeing intense market interest as the AI infrastructure cycle drives a massive re-rating of storage and memory providers, leading to a surge in both institutional accumulation and retail FOMO. Community discussions are split between those riding the momentum of this data-heavy supercycle and skeptics cautioning that the rapid price expansion is showing signs of an overextended speculative bubble.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is gaining significant community attention as shareholders push for a short squeeze, fueled by bullish sentiment surrounding its international expansion and the potential impact of new celebrity partnerships. Investors are actively discussing the stock's consolidation near technical support levels while emphasizing its long-term growth potential and strong product presence compared to competitors.

Magnite, Inc. provides a technology solution to automate the purchase and sale of digital advertising inventory for buyers and sellers. It features applications and services for digital advertising sellers including websites, mobile applications, and other digital media properties. The company was founded by Frank Addante, Duc Chau, Craig Roah, Julie Mattern and Brian D. Baumgart on April 20, 2007 and is headquartered in New York, NY.

Magnite Inc

Magnite is currently trending as investors react to strong earnings results that highlighted significant CTV growth and reaffirmed a commitment to aggressive share repurchases. The community is actively discussing the company's essential role in the programmatic advertising ecosystem and its potential as a prime candidate for consolidation as the ad-tech sector undergoes AI-driven transformation.

Rackspace Technology, Inc. engages in the provision of end-to-end multi-cloud technology services. The firm designs, builds and operates its customers’ cloud environments across technology platforms. It operates through the following segments: Multicloud Services and Apps & Cross Platform. The Multicloud Services segment includes public and private cloud managed services offerings, as well as professional services related to designing and building multicloud solutions and cloud-native applications. The Apps & Cross Platform segment includes managed applications, managed security and data services, as well as professional services related to designing and implementing application, security and data services. The company was founded on July 21, 2016 and is headquartered in San Antonio, TX.

Rackspace Technology Inc

Rackspace Technology is trending due to a major partnership with AMD to deploy AI compute infrastructure, fueling a narrative around the company's transformation into a specialized AI infrastructure provider. The community is actively discussing the stock's potential for a significant squeeze, focusing on high institutional ownership and the strategic shift toward high-margin enterprise AI sectors.

Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF

Tradr 2X Long ASTS Daily ETF

ASTX is trending as traders use the 2X leveraged ETF to capitalize on high-conviction volatility surrounding AST SpaceMobile, particularly as the community closely tracks upcoming satellite launch events and market momentum. While some participants view the instrument as a high-reward tool for amplifying gains, others are actively debating the inherent risks of daily decay and extreme price swings associated with this leveraged product.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is attracting significant community interest driven by persistent insider buying from CEO Anthony Noto and speculation regarding an upcoming shareholder meeting. Investors are closely monitoring its technical breakout potential while debating the stock's future role as a financial platform amid broader rate-sensitive market trends.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is gaining significant community attention as investors anticipate the upcoming launch of its predictive liquidity allocation mechanism and expansion to the Ethereum mainnet. Discussion is driven by bullish sentiment regarding its role in the Base ecosystem and potential as a key piece of liquidity infrastructure.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2024 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is trending as traders analyze the impact of recent takeover chatter involving Netflix, which has sparked significant volatility and speculation about the company's valuation as a potential acquisition target. While the streaming giant has reportedly pushed back on these rumors, the community remains intensely focused on the studio's extensive IP library and the potential for a competitive bidding war.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors weigh strong Phase 3 data for Axpaxli against concerns over FDA approval requirements for a single-trial NDA and recent legal disputes with competitor EyePoint. The community remains deeply divided, with bulls pointing to high institutional ownership and buyout potential, while bears focus on the regulatory hurdles, ongoing litigation, and lackluster recent stock performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five...

Unicycive Therapeutics (NASDAQ:UNCY) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Unicycive Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

B. Riley Financial Begins Coverage on Unicycive Therapeutics (NASDAQ:UNCY)

B. Riley Financial assumed coverage on shares of Unicycive Therapeutics in a report on Friday. They issued a "buy" rating and a $22.00 price target on the stock...

Equities Analysts Offer Predictions for UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for Unicycive Therapeutics in a research note issued on Tuesday, April 7th. Brookline Capital Markets analyst K. Raja expects that the company will post...

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Moderate Buy" by Brokerages

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assi...

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, April 9, 2026 NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...

Brookline Capital Markets Estimates UNCY Q2 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Brookline Capital Markets issued their Q2 2026 earnings per share estimates for shares of Unicycive Therapeutics in a report issued on...

Benchmark Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $15.00

Benchmark lowered their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a "speculative buy" rating for the company in a research note on Monday...

HC Wainwright Issues Positive Estimate for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now anticipates that the company will post...

Guggenheim Has Lowered Expectations for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price

Guggenheim decreased their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday...

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Current Price	$7.17
Prev Close	$7.12
Open	$7.12
Dividend Yield	0.00%
50-Day Moving Average	$7.43
Beta	0.82
Avg. Volume	692,050.17
PE Ratio	-3.49

52-Week High	$8.74
52-Week Low	$3.71
Market Capitalization	$190.1M
EPS (Annual)	-$1.67
Price to Book	4.80
Revenue Per Employee	$0.00

UNCYUnicycive Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest UNCY News